Journal article
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Abstract
BACKGROUND: The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mutations. The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients with platinum-sensitive, recurrent, …
Authors
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H
Journal
The Lancet Oncology, Vol. 16, No. 1, pp. 87–97
Publisher
Elsevier
Publication Date
January 2015
DOI
10.1016/s1470-2045(14)71135-0
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, IntravenousAdministration, OralAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinCarboplatinDisease-Free SurvivalDrug Administration ScheduleEnzyme InhibitorsFemaleHumansMiddle AgedMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm Recurrence, LocalNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPaclitaxelPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesTime FactorsTreatment OutcomeYoung Adult